Opportunity Information: Apply for RFA HG 17 009
Implementing Genomics in Practice (IGNITE) II: Pragmatic Clinical Trials Enhanced Diversity Clinical Groups (U01) is a National Institutes of Health (NIH) funding opportunity (RFA HG 17 009) that supports participation in the IGNITE II Pragmatic Clinical Trials Network. The core purpose of this network is to run pragmatic clinical trials in real health care environments to figure out when and how genomic medicine interventions actually improve patient care outside of tightly controlled research settings. The program is designed to generate evidence that is directly usable by health systems, clinicians, payers, and policymakers, with an emphasis on answering practical questions about clinical utility (whether the genomic intervention leads to better health decisions or outcomes) and cost-effectiveness (whether the benefits justify the costs in routine care).
A central feature of this FOA is its strong focus on diversity and equity in clinical research participation. Applicants are expected to recruit at least 75 patients drawn from racial or ethnic minority populations, underserved populations, or groups that experience poorer medical outcomes. This requirement is explicitly higher than the companion announcement (RFA HG-17-008), which expects a minimum of 35 such participants, signaling that this particular opportunity is meant to strengthen the evidence base for genomic medicine in populations that have historically been underrepresented in genomics research and may face barriers to access or benefit. In practice, this means proposed trials should be designed to work in varied, real-world clinical settings and should thoughtfully address recruitment, engagement, retention, and implementation challenges that can disproportionately affect these communities.
The trials supported through the IGNITE II network are intended to be pragmatic, meaning they are embedded in routine clinical workflows and aim to produce generalizable knowledge. The network is expected to evaluate approaches for implementing genomic medicine in diverse health care settings, and to clarify which genomic interventions are ready for randomized clinical trials versus those that may require different evidence-building strategies. Another key objective is to develop and refine effective methods for conducting these kinds of trials, including the practicalities of integrating genomic testing, returning results, supporting clinical decision-making, and measuring downstream outcomes in everyday care.
This opportunity uses a U01 cooperative agreement mechanism, which typically indicates substantial scientific or programmatic involvement by NIH staff compared to standard research project grants. In cooperative agreements, awardees generally collaborate as part of a coordinated program or network, aligning on common goals, shared measures, and cross-site learning. Here, that structure supports the larger IGNITE II goal of producing broadly applicable implementation and outcomes evidence rather than isolated, single-site findings.
Eligibility is broad across U.S.-based organizations and includes many public and private entities such as state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; tribal organizations other than federally recognized tribal governments; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses. The FOA also highlights additional eligible applicant types that are often key partners for reaching underserved communities, including faith-based or community-based organizations; Historically Black Colleges and Universities (HBCUs); Hispanic-serving institutions; Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with U.S. territories or possessions and certain regional organizations.
At the same time, the opportunity clearly restricts foreign participation. Non-domestic (non-U.S.) entities are not eligible to apply as foreign institutions, and non-domestic components of U.S. organizations are not eligible. In addition, foreign components, as defined by the NIH Grants Policy Statement, are not permitted. This means applicants must plan to carry out the supported work entirely through eligible U.S.-based organizations and components.
In terms of administrative details provided, the opportunity is categorized as discretionary funding, uses the cooperative agreement funding instrument, and falls under the health funding activity category (CFDA 93.172). The posting indicates an original closing date of 2017-11-04 and a creation date of 2017-07-25. While the excerpt does not list an award ceiling or expected number of awards, the overall structure indicates NIH intends to build a coordinated set of clinical groups capable of running rigorous, real-world genomic medicine trials with a deliberate emphasis on improving representation and relevance for populations that are often left out of genomics research and that may bear a disproportionate burden of disease.Apply for RFA HG 17 009
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Implementing Genomics in Practice (IGNITE) II: Pragmatic Clinical Trials Enhanced Diversity Clinical Groups (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2017-07-25.
- Applicants must submit their applications by 2017-11-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the full title of this funding opportunity?
The opportunity is titled "Implementing Genomics in Practice (IGNITE) II: Pragmatic Clinical Trials Enhanced Diversity Clinical Groups (U01)."
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What is the FOA identifier for this opportunity?
The funding opportunity announcement (FOA) is identified as RFA HG 17 009.
What program or network does this FOA support?
It supports participation in the IGNITE II Pragmatic Clinical Trials Network.
What is the main purpose of the IGNITE II Pragmatic Clinical Trials Network?
The core purpose is to run pragmatic clinical trials in real health care environments to determine when and how genomic medicine interventions improve patient care outside of tightly controlled research settings.
What does "pragmatic clinical trial" mean in the context of this FOA?
In this context, pragmatic trials are embedded in routine clinical workflows and are designed to generate generalizable knowledge from everyday care settings rather than highly controlled research environments.
What kinds of questions are these trials intended to answer?
The program emphasizes practical questions about clinical utility (whether the genomic intervention leads to better health decisions or outcomes) and cost-effectiveness (whether the benefits justify the costs in routine care).
Who is expected to use the evidence generated by this program?
The evidence is intended to be directly usable by health systems, clinicians, payers, and policymakers.
What is the diversity and equity focus of this FOA?
A central feature is a strong focus on diversity and equity in clinical research participation, with expectations that supported trials strengthen the evidence base for genomic medicine in populations historically underrepresented in genomics research and/or facing barriers to access or benefit.
Is there a minimum requirement for enrolling participants from underrepresented or underserved groups?
Yes. Applicants are expected to recruit at least 75 patients drawn from racial or ethnic minority populations, underserved populations, or groups that experience poorer medical outcomes.
How does the diversity enrollment expectation compare to the companion announcement mentioned?
This FOA has a higher minimum expectation (75 such participants) than the companion announcement (RFA HG-17-008), which expects a minimum of 35 such participants.
Which participant groups count toward the enhanced diversity focus described in the FOA?
The FOA specifies racial or ethnic minority populations, underserved populations, or groups that experience poorer medical outcomes.
What practical challenges are applicants expected to address for these populations?
Proposed trials should thoughtfully address recruitment, engagement, retention, and implementation challenges that can disproportionately affect these communities.
What types of clinical settings are these studies expected to operate in?
The trials are intended to work in varied, real-world clinical settings and be integrated into routine care.
What kinds of genomic medicine activities or workflow elements does the FOA highlight?
The FOA highlights integrating genomic testing, returning results, supporting clinical decision-making, and measuring downstream outcomes in everyday care.
Does the network have goals beyond running trials?
Yes. Another key objective is to develop and refine effective methods for conducting pragmatic genomic medicine trials, including practical integration and measurement in routine care.
What does the FOA say about determining readiness for randomized clinical trials?
The network is expected to clarify which genomic interventions are ready for randomized clinical trials versus those that may require different evidence-building strategies.
What funding mechanism is used?
This opportunity uses the U01 cooperative agreement mechanism.
What does a U01 cooperative agreement imply for how projects are run?
A U01 cooperative agreement typically indicates substantial scientific or programmatic involvement by NIH staff compared to standard research project grants, and awardees generally collaborate as part of a coordinated program or network.
What does collaboration look like under this cooperative agreement approach?
The description indicates awardees collaborate within a coordinated network, aligning on common goals, shared measures, and cross-site learning to produce broadly applicable evidence rather than isolated single-site findings.
Is eligibility limited to certain types of organizations?
Eligibility is broad across U.S.-based organizations and includes many public and private entities (government, education, nonprofit, and for-profit, among others), as described in the opportunity information.
Which government entities are listed as eligible applicants?
Eligible government entities include state, county, and local governments, as well as special district governments.
Are educational institutions eligible?
Yes. Eligible applicants include independent school districts and public and state-controlled institutions of higher education, as well as private institutions of higher education.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments are eligible, and tribal organizations other than federally recognized tribal governments are also listed as eligible.
Are housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are included among eligible applicants.
Are nonprofits eligible even if they do not have 501(c)(3) status?
Yes. Nonprofit organizations with or without 501(c)(3) status are listed as eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible.
Does the FOA encourage participation by organizations connected to underserved communities?
The FOA highlights additional eligible applicant types that are often key partners for reaching underserved communities, including faith-based or community-based organizations and several categories of minority-serving institutions.
Which minority-serving institutions are explicitly highlighted as eligible?
The FOA highlights Historically Black Colleges and Universities (HBCUs); Hispanic-serving institutions; Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are highlighted among additional eligible applicant types.
Are foreign (non-U.S.) organizations eligible to apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply as foreign institutions.
Can a U.S. organization include a non-domestic component in the proposed work?
No. Non-domestic components of U.S. organizations are not eligible.
Are foreign components permitted under this FOA?
No. Foreign components (as defined by the NIH Grants Policy Statement) are not permitted.
What does the foreign participation restriction mean in practical terms?
Applicants must plan to carry out the supported work entirely through eligible U.S.-based organizations and components.
How is this opportunity categorized in terms of funding type?
The posting categorizes it as discretionary funding.
What is the funding instrument type?
It uses the cooperative agreement funding instrument.
What is the funding activity category?
It falls under the health funding activity category.
What CFDA number is associated with this opportunity?
The CFDA number listed is 93.172.
What are the key dates provided in the posting?
The posting lists a creation date of 2017-07-25 and an original closing date of 2017-11-04.
Does the provided excerpt list an award ceiling or the expected number of awards?
No. The excerpt does not list an award ceiling or an expected number of awards.
What is the intended overall outcome of funding these clinical groups?
The structure indicates NIH intends to build a coordinated set of clinical groups capable of running rigorous, real-world genomic medicine trials, with a deliberate emphasis on improving representation and relevance for populations often left out of genomics research and that may bear a disproportionate burden of disease.
Browse more opportunities from the same category: Health
Next opportunity: Food and Agricultural Sciences National Needs Graduate and Postgraduate Fellowship (NNF) Grants Program
Previous opportunity: Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 17 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 17 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| Tailoring Cardiac Rehabilitation to Enhance Participation of Older Adults (R01) Apply for RFA AG 18 016 Funding Number: RFA AG 18 016 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Domestic Violence Prevention Initiative Apply for HHS 2017 IHS DVPI 0001 Funding Number: HHS 2017 IHS DVPI 0001 Agency: Indian Health Service Category: Health Funding Amount: $208,000 |
| Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp) Apply for PA 17 442 Funding Number: PA 17 442 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03) Apply for PAR 17 439 Funding Number: PAR 17 439 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Metabolomic Data Analysis and Interpretation Tools (U01) Apply for RFA RM 17 012 Funding Number: RFA RM 17 012 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Compound Identification Development Cores (U2C) Apply for RFA RM 17 013 Funding Number: RFA RM 17 013 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| National Metabolomics Data Repository (NMDR) (U2C) Apply for RFA RM 17 011 Funding Number: RFA RM 17 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stakeholder Engagement and Program Coordination Center (SEPCC) (U2C) Apply for RFA RM 17 014 Funding Number: RFA RM 17 014 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Point of Care Technologies Research Network: Point of Care Centers (U54) Apply for PAR 17 453 Funding Number: PAR 17 453 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| NIBIB Exploratory/Developmental Research Grant Program (R21) Apply for PAR 17 441 Funding Number: PAR 17 441 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIAID Research Education Program (R25) Apply for PAR 17 455 Funding Number: PAR 17 455 Agency: National Institutes of Health Category: Health Funding Amount: $325,000 |
| NINDS CREATE Bio Optimization Track for Biologics (U44) Apply for PAR 17 457 Funding Number: PAR 17 457 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Control and Elimination Program for NTD Apply for SOL OAA 17 000122 Funding Number: SOL OAA 17 000122 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Bio Optimization Track for Biologics (U01) Apply for PAR 17 456 Funding Number: PAR 17 456 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Metabolomics Core for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 015 Funding Number: RFA RM 17 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54) Apply for RFA RM 17 017 Funding Number: RFA RM 17 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Coordinating Center for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 018 Funding Number: RFA RM 17 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Sites for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 019 Funding Number: RFA RM 17 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sequencing Core(s) for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 016 Funding Number: RFA RM 17 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for Countermeasures Against Select Pathogens (R01) Apply for RFA AI 17 026 Funding Number: RFA AI 17 026 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 17 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.